Iontophoretic tumor therapy
For this innovative
development in the field of the cancer therapy contact
to the pharmaceutical industry or to special research
institutes and oncological hospitals is sought.
This method resulted from the practice as the life work of a long-standing
clinician. It is an unchallenged method, which employs a new
tumor destroying medication of selective effect and curing aim void of
significant adverse effects. Based on school medicine, the iontophoretic
tumor therapy is no procedure of the alternative medicine and no
outsider method, but an original scientific development.
The medication developed for the iontophoretic tumor therapy was
subject of extensive scientific toxicological examinations executed
by a renowned company meeting highest scientific standards, which
have proved its non-toxic character. The scientist responsible for
the examinations summarized: “From the toxicological view,
the planned application in man ought to be considered safe. Also,
pharmacological interactions in the sense of adverse effects can
hardly be expected at doses administered in man. From my point of
view all legal standards governing the manufacture and prescription
of drugs are fulfilled.”
This medicine is a priori no cytostatic: however, the agent is
transformed exclusively at the site of effect (only then and only
there!) into a highly potent selective antineoplastic drug due to
Iontophoresis effects. Its main active agent is
an ionic acridine derivative, transported extra- and intracellular
under iontophoretic
conditions. The result is a selective admission of the substance
to the nuclei of the tumor cells with the subsequent death of these
cells. Since Iontophoresis affects exclusively nuclear membranes,
only tumor tissues are permeated by the medication, an effect, which
fails to appear in healthy tissues. This biological phenomenon constitutes
the uniqueness of the iontophoretic tumor therapy. It also explains
the selectivity and allows to understand the excellent treatment
results. Electrical current intensities
and current densities used for the Iontophoresis are in
a physiological range at milliamps; they are not
traumatic, well tolerated. The technical apparatus needed for the
application of the method is comparatively
low. As for the complete iontophoretic tumor therapy developed
by the inventor/inaugurator, medication and Iontophoresis form a
key and lock principle tuned subtly with each other. I.e.: neither
the medication can be replaced by another substance nor can the Iontophoresis
be replaced by another electrical modality.
So far, the primary application of the antineoplastic tumor Iontophoresis
was the organ conserving therapy and relapse prophylaxis of the bladder
cancer. Long-standing clinical results and scientific publications
are already available so this method is an advanced clinical
procedure. Early on, considerations started to transfer this
underlying principle to tumors of other organs. It was only in 2003 that a corresponding
model was developed.
The iontophoretic modality found now allows to precisely and selectively
direct the current to tumors at various locations within the body
exerting the selective antineoplastic effect at exactly defined current
intensities and current densities. However, detailed treatment
concepts for malignancies of the lung and mamma available now could not yet
be practically realized. Obviously, no therapeutic success can be
guaranteed at this moment. There are, however, good chances that
success is to be expected.
This optimism is nurtured by excellent results achieved with the
iontophoretic tumor therapy of the bladder and with reproducible
animal experiments. The latter were extended inoculation
tumors,
which regressed without exception completely due to a single antineoplastic
Iontophoresis. Follow-up was 2 years until the natural death of the
laboratory animals. During this time, animals were at good general
conditions with no accounts of a relapse. According to literature,
the experimental tumors chosen previously resisted all other forms
of therapy. Further support comes from the almost biological order
the selective iontophoretic mechanism exhibits in combination with
the special medication. Bladder and skin tumors treated with antineoplastic
Iontophoresis, the selectivity was regularly faultlessly clinically
proven and documented.
It needs to be stressed that the principle of the selective antineoplastic
iontophoresis not only applies to proliferative cells of the tumor,
but also for its quiescent cells. This not only stops the tumor growth
but results a complete tumor remission, as was already shown by the
experiments mentioned above.
Evidence for the effectiveness of the iontophoretic tumor
therapy at other internal organs, however, can only be
secured by specific
curative tests. Diligent execution will likely
exclude harm of the patients. The 'primum nil nocere' is thus ensured.
As in the bladder,
when applied to other sites the iontophoretic tumor therapy should
be easily manageable, non-toxic and selective. With
respect to the toxicological testing of the medication mentioned
above, the scheduled
dosage will be completely within legal limits and by far below those
causing adverse effects or being toxic. From a pharmacological point
of view, there are “light years” between therapeutic
concentrations and those being toxic. This fact is also underpinned
by the fact that the medication kills all cells in cell cultures
at
the inconceivable concentration of 0.05 µ/g (= 50 billionth
of a gram).
Curative tests are permitted legally with medication not yet admitted.
They can be carried out in individual cases to patients who decline
heroic radical operations and chemotherapies, looking for treatment,
which appears an alternative and only little stressing. The stress
due to 1-3 cycles of the iontophoretic tumor therapy cannot be compared
with conventional surgical interventions and usual chemotherapy.
In case the iontophoretic tumor therapy has no success, therapies
using those conventional methods can be immediately changed to. The
delay accepted for use of the iontophoretic tumor therapy can be
justified from a physician’s standpoint. The risk for patient
and doctor is therefore low.
It is the creed of the inaugurator of the iontophoretic tumor therapy,
to consider this innovative method not only as an expansion of the
existing therapeutic repertoire, but also as a potential method
of different therapeutic dimension.
It is the declared aim of this gentle antineoplastic tumor iontophoresis
as a curative therapy to do in as many cases as possible for the
most frequent cancers without mutilating operations, without conventional
chemotherapy and without palliative radiation therapy which shorten
the life and reduce the quality of life of patients. This aim is
already accomplished for malignancies of the bladder, with the exception
of very advanced stages. For other organs, this aim is at hand.
This opens a rewarding field not yet developed for interested
oncologists for practical and scientific
activity beyond the everyday routine
of conventional cancer therapies. At the present stage, the realization
of the aim outlined above can no longer be achieved by the inaugurator
of the method himself, which is the reason why he tries this way
to win a comrade-in-arms to tackle this humanitarian task.
The production of the new (and still not authorized) preparation
is protected by patents in the USA and Germany. The protective rights
are in the possession of the inventor/inaugurator just like the
pleasant and catchy trademark under which the preparation shall be
commercialized.
It is intended to entrust the patents including the complete clinical
and technical know-how to a qualified enterprise, for exclusive usage,
which is ready to tackle the task and challenge also in the humanitarian
aspect of this innovation.
You are asked
to contact using e-mail in case of serious technical
interest disclosing the qualification and profile of the enterprise/institution.
Further information concerning antineoplastic iontophoresis of the
bladder carcinoma and selectivity:
Bladder Carcinoma
Iontophoretic tumor therapy of the bladder carcinoma is a fully
developed clinical method. Medicine (instillat) is being transported
iontophoretically from the bladder lumen into the tumor respectively
the bladder wall. Here – under the influence of iontophoresis – it
develops its selective antineoplastic effect (=permeability of core
membrane only in the tumor cell, and iontophoretic transportation of
the medicine into the nucleus entailing cell death).
With this method it is possible to locate and destroy tumors
even in deeper tissues of the bladder wall as well as
latent and at first diagnosis optically not detectable ubiquitous tumor
sprouts in all bladder wall sections and layers. These
non-evident tumor sprouts produce most of the time in chronological
graduation and multi ocular the so-called relapses that are after
all a new manifestation of the tumor. This constellation constitutes
the actual prognostic, therapeutic, and prophylactic dilemma of
the bladder carcinoma.
Antineoplastic iontophoresis therefore allows genuine relapse
prophylaxis in all stages of the illness. Every specialist/urologist
knows how important effective relapse prophylaxis is during the
treatment of bladder cancer. Real cure can only be achieved through
relapse prophylaxis. Conventional cytostatic bladder instillation
therapies do not have this ability, at least when it comes to deeper
infiltrating areas. They cannot spontaneously penetrate deep enough
into the bladder wall, are not selective, and have other serious
side effects.
The new method can in many cases avoid mutilating cystectomy,
surgery from which - according to American statistics - only 10 – 20
% of patients benefit anyway. In 50% of the operated cases distant
metastases occur within two years, in spite of (or because of) intensive
pre- and postoperative chemotherapy. Compared to conventional therapy
schemes the iontophoretic tumor therapy of bladder cancer is a patient
friendly, gentle, and bladder conserving method with an efficiency
that in the past could not be imagined. Thus the bladder carcinoma
can be considered as classical application area for
the iontophoretic tumor therapy.
In 1994 statistics was compiled (Positive List)
about 43 cases of different stages of bladder carcinoma
having been treated by iontophoretic tumor therapy. Treatment was
finished in all patients in 1993. Follow-up varied between one and
five years. At the checkups all patients were bladder healthy,
free of relapses and in good general condition.
20 patients, having been treated with antineoplastic
iontophoresis, could be followed up till the end of 2003. They were
free of relapses and in good general condition. The unusually
long period of follow-ups was 10 years!
Selectivity
During iontophoretic tumor therapy of the bladder
carcinoma the whole bladder lies within the sphere of influence
of iontophoresis and medicine. If the method were not selective,
heavy cytotoxic effects – likewise in the predominantly healthy
parts of the bladder - would occur. Within the 103 cases treated
this way this has never been observed, although some of them underwent
several iontophoretic treatment cycles.
The new method’s selectivity can especially easily be proven
with skin tumors. Photo-documentation of
patients suffering from basal cell carcinoma in
the face, who had been treated with antineoplastic iontophoresis
verify selectivity in a particularly impressive way: The
destroyed tumor can sharply be demarcated from the surrounding healthy
tissue.
|